|
Bar-Or A, Wiendl H, Montalban X, Alvarez E, Davydovskaya M, Delgado SR, Evdoshenko EP, Giedraitiene N, Gross-Paju K, Haldre S, Herrman CE, Izquierdo G, Karelis G, Leutmezer F, Mares M, Meca-Lallana JE, Mickeviciene D, Nicholas J, Robertson DS, Sazonov DV, Sharlin K, Sundaram B, Totolyan N, Vachova M, Valis M, Bagger M, Haring DA, Ludwig I, Willi R, Zalesak M, Su W, Merschhemke M, Fox EJ. Rapid and sustained B-cell depletion with subcutaneous ofatumumab in relapsing multiple sclerosis: APLIOS, a randomized phase-2 study. Mult Scler. 2022 May;28(6):910-924. doi: 10.1177/13524585211044479. Epub 2021 Oct 4. PubMed PMID: 34605319; PubMed Central PMCID: PMC9024029.
AÑO: 2022; IF: 5.8
|
34605319
|
Brieva L, Estruch BC, Merino JAG, Meca-Lallana V, Rio J, Rodriguez-Antiguedad A, Aguera E, Ara JR, Luque AA, Garcia CA, Blanco Y, Castillo-Trivino T, Costa-Frossard L, Gonzalez Platas M, Pascual LL, Llaneza-Gonzalez M, Gines MLM, Matias-Guiu J, Meca-Lallana JE, Bilbao MM, Sempere AP, Romero-Pinel L, Saiz A, Moral E. Disease modifying therapy switching in relapsing multiple sclerosis: A Delphi consensus of the demyelinating expert group of the Spanish society of neurology. Mult Scler Relat Disord. 2022 Jul;63:103805. doi: 10.1016/j.msard.2022.103805. Epub 2022 Apr 12. PubMed PMID: 35512501.
AÑO: 2022; IF: 4.0
|
|
Mutukula N, Man Z, Takahashi Y, Iniesta Martinez F, Morales M, Carreon-Guarnizo E, Hernandez Clares R, Garcia-Bernal D, Martinez Martinez L, Lajara J, Nunez Delicado E, Meca Lallana JE, Izpisua Belmonte JC. Generation of RRMS and PPMS specific iPSCs as a platform for modeling Multiple Sclerosis. Stem Cell Res. 2021 May;53:102319. doi: 10.1016/j.scr.2021.102319. Epub 2021 Apr 15. PubMed PMID: 33894548.
AÑO: 2021; IF: 1.587
|
|
Reich DS, Arnold DL, Vermersch P, Bar-Or A, Fox RJ, Matta A, Turner T, Wallstrom E, Zhang X, Mares M, Khabirov FA, Traboulsee A; Tolebrutinib Phase 2b Study Group. Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhibitor, in relapsing multiple sclerosis: a phase 2b, randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2021 Sep;20(9):729-738. doi: 10.1016/S1474-4422(21)00237-4. PubMed PMID: 34418400; PubMed Central PMCID: PMC8434816.
AÑO: 2021; IF: 59.935
|
|
Meca-Lallana J, Garcia-Merino JA, Martinez-Yelamos S, Vidal-Jordana A, Costa L, Eichau S, Rovira A, Brieva L, Aguera E, Zarranz AR. Identification of patients with relapsing multiple sclerosis eligible for high-efficacy therapies. Neurodegener Dis Manag. 2021 Jun;11(3):251-261. doi: 10.2217/nmt-2020-0049. Epub 2021 May 10. PubMed PMID: 33966475.
AÑO: 2021
|